These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 22900848

  • 41. Expression of angiogenic factors in craniopharyngiomas: implications for tumor recurrence.
    Sun HI, Akgun E, Bicer A, Ozkan A, Bozkurt SU, Kurtkaya O, Koc DY, Pamir MN, Kilic T.
    Neurosurgery; 2010 Apr; 66(4):744-50; discussion 750. PubMed ID: 20190664
    [Abstract] [Full Text] [Related]

  • 42. Evaluation of imatinib mesylate effects on glioblastoma aggressiveness with SPECT radiotracer 99mTc-(v)-DMSA.
    Le Jeune N, Dubois F, Bin V, Perek N.
    Eur J Cancer; 2006 May; 42(8):1004-13. PubMed ID: 16564690
    [Abstract] [Full Text] [Related]

  • 43. Up-regulation of platelet-derived growth factor-A is responsible for the failure of re-initiated interferon alpha treatment in hepatocellular carcinoma.
    Zhang JB, Sun HC, Jia WD, Zhuang PY, Qian YB, Zhu XD, Kong LQ, Wang L, Wu WZ, Tang ZY.
    BMC Cancer; 2012 Oct 01; 12():439. PubMed ID: 23025904
    [Abstract] [Full Text] [Related]

  • 44. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations.
    Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D, Booser DJ, Green MC, Arun BK, Pusztai L, Lopez A, Islam R, Valero V, Hortobagyi GN.
    Ann Oncol; 2008 Oct 01; 19(10):1713-9. PubMed ID: 18515258
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis.
    Horak P, Wöhrer A, Hassler M, Hainfellner J, Preusser M, Marosi C.
    J Neurooncol; 2012 Sep 01; 109(2):323-30. PubMed ID: 22610940
    [Abstract] [Full Text] [Related]

  • 47. KIT and PDGF as targets.
    Verweij J.
    Cancer Treat Res; 2004 Sep 01; 120():117-27. PubMed ID: 15217221
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Expression of Kit and platelet-derived growth factor receptors alpha and beta in cholangiocarcinoma, and case report of therapy with imatinib mesylate (STI571).
    Holcombe RF, Gu M, Imagawa D, Milovanovic T.
    Anticancer Drugs; 2003 Sep 01; 14(8):651-7. PubMed ID: 14501388
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.
    Huh WK, Sill MW, Darcy KM, Elias KM, Hoffman JS, Boggess JF, Alvarez RD, Long HJ, O'Malley DM, Birrer MJ.
    Gynecol Oncol; 2010 May 01; 117(2):248-54. PubMed ID: 20189232
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
    Ivan D, Niveiro M, Diwan AH, Eton O, Kim KB, Lacey C, Gonzalez C, Prieto VG.
    J Cutan Pathol; 2006 Apr 01; 33(4):280-5. PubMed ID: 16630177
    [Abstract] [Full Text] [Related]

  • 56. Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/ß expression in squamous cell carcinoma of the head and neck in vitro.
    Schultz JD, Rotunno S, Riedel F, Anders C, Erben P, Hofheinz RD, Faber A, Thorn C, Sommer JU, Hörmann K, Sauter A.
    Int J Oncol; 2011 Apr 01; 38(4):1001-12. PubMed ID: 21249316
    [Abstract] [Full Text] [Related]

  • 57. Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis.
    Leipner C, Grün K, Müller A, Buchdunger E, Borsi L, Kosmehl H, Berndt A, Janik T, Uecker A, Kiehntopf M, Böhmer FD.
    Cardiovasc Res; 2008 Jul 01; 79(1):118-26. PubMed ID: 18326555
    [Abstract] [Full Text] [Related]

  • 58. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.
    Homsi J, Daud AI.
    Cancer Control; 2007 Jul 01; 14(3):285-94. PubMed ID: 17615535
    [Abstract] [Full Text] [Related]

  • 59. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis.
    Campbell JS, Johnson MM, Bauer RL, Hudkins KL, Gilbertson DG, Riehle KJ, Yeh MM, Alpers CE, Fausto N.
    Differentiation; 2007 Nov 01; 75(9):843-52. PubMed ID: 17999742
    [Abstract] [Full Text] [Related]

  • 60. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats.
    Fernandez M, Mejias M, Garcia-Pras E, Mendez R, Garcia-Pagan JC, Bosch J.
    Hepatology; 2007 Oct 01; 46(4):1208-17. PubMed ID: 17654489
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.